Description: Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS115, which is in Phase II trial for the treatment of Parkinson's disease. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2015 and is headquartered in Jupiter, Florida.
Home Page: jupiterneurosciences.com
JUNS Technical Analysis
1001 North US Highway 1
Jupiter,
FL
33477
United States
Phone:
561 406 6154
Officers
| Name | Title |
|---|---|
| Mr. Christer Rosen | Co-Founder, CEO & Chairman of the Board |
| Ms. Alison D. Silva MA, MS | President, Chief Business Officer & Director |
| Dr. Marshall Hayward Ph.D. | Co-Founder, Chief Scientific Officer & Director |
| Mr. Alexander Rosen | Co-Founder & Chief Administrative Officer |
| Dr. Claes Wahlestedt M.D., Ph.D. | Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer |
| Dr. Shaun P. Brothers Ph.D. | Co-Founder, Consulting VP of Scientific Research & Member of Scientific Advisory Board |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-12-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |